Thus, the ovarian cancer patients with raised plasma concentrations of Ang1 and low Tie2 benefited most from bevacizumab, when concurrently treated with carboplatin and paclitaxel values [84]. The gene discussed is TEK; the disease is ovarian carcinoma.